Company Overview and News

 
[Press] Blue Energy June 2018 Quarterly Report

2018-07-31 oilvoice
Blue Energy Limited (ASX: “BUL”) is pleased to report on activities during the June 2018 quarter across its exploration acreage in Queensland and the Northern Territory in which the Company'skey gas and oil projects are located.
GLL BUL COI COMRF BLELF APA

 
Amzalak edges out Ellis to win the Shares Race

2018-07-14 smh.com.au
In a tight race at the top all the way through, Mendy Amzalak of AMZ Capital edges ahead of Angie Ellis of 20/20 Investments to take top spot in the final week of the four-week race.
GLL OPG OPSGF DIG CCLFF

 
Clear pecking order emerges in week three of the Shares Race

2018-07-07 smh.com.au
Week three of the four-week Shares Race sees the establishment of a clear pecking order at the top, following last week when hardly anything separated the first-three placeholders last week.
GLL OPG OPSGF DIG CCLFF

 
Three-way tussle for glory in the Shares Race

2018-06-30 smh.com.au
Although Angie Ellis of 80 20 Investments holds a tiny lead with $123,796, Richard Pritchard, who plays as the Chartist, is only a couple of hundred of dollars behind her.
GLL DIG CCLFF

 
Amzalak closes in on leader Ellis as Jatenergy goes gangbusters

2018-03-23 smh.com.au
Mendy Amzalak of AMZ Capital has narrowed the gap with race leader Angie Ellis of 80 20 Investments, in week three of the four-week shares race.
GLL ORNGF CYYNF CYP ORNQF OGX

 
Ellis maintains lead as Smart Park fires up

2018-03-17 smh.com.au
Angie Ellis of 80 20 Investments has maintained her lead over her closest rival, Mendy Amzalak of AMZ Capital, in week two of the four-week shares race with her original $100,000 portfolio worth $114,584.
GLL ORNGF CYYNF CYP ORNQF OGX

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...